STAT+: Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Prime Medicine won an arbitration dispute against Beam Therapeutics, with an arbitrator ruling that Prime's work on a gene-editing drug for alpha-1 antitrypsin deficiency (AATD) did not violate a 2019 agreement designed to prevent the two companies from competing.
- The 2019 agreement was struck when both companies were spun out of the same lab, and it had restricted Prime's ability to operate in overlapping disease areas with Beam.
- Prime Medicine's AATD clinical trial can now begin this quarter, a timeline the arbitration had previously left uncertain.
- Prime Medicine's stock rose 11% in Wednesday morning trading following the ruling.
- Beam Therapeutics absorbed the loss in the dispute, marking a setback for the rival gene-editing company.
Why it matters: With arbitration cleared, Prime Medicine can advance its AATD gene-editing program into clinical trials this quarter while rival Beam Therapeutics loses leverage from the 2019 non-compete agreement — Prime's 11% stock jump reflects how much was riding on the arbitrator's decision.
